Group 1 - Yuwang Biological Nutrition Co., Ltd. has submitted its prospectus and is preparing for an IPO on the Hong Kong Stock Exchange [1] - Prior to restructuring, Yuwang Pharmaceutical declared a dividend of 320 million RMB in December 2024, with Yuwang Biological Nutrition's payable dividend amounting to 55.8 million RMB [2] - For the first half of the year, Yuwang Biological Nutrition reported revenue of 340 million RMB, with a profit decline of 74% year-on-year [3] Group 2 - Yuwang Biological Nutrition's revenue for 2022, 2023, and 2024 is projected to be 534 million RMB, 661 million RMB, and 832 million RMB respectively, with gross profits of 136 million RMB, 185 million RMB, and 216 million RMB [3][4] - The gross profit margins for the same years are 25.4%, 28.1%, and 26% [3][4] - The net profit for 2022, 2023, and 2024 is estimated at 67.3 million RMB, 102 million RMB, and 125.3 million RMB, with net profit margins of 12.6%, 15.4%, and 15.1% [4][5] Group 3 - As of June 30, 2025, Yuwang Biological Nutrition's net asset value is reported to be 71.3 million RMB [6] - The company has non-current assets of 96.3 million RMB and current assets of 331.9 million RMB as of the same date [6] - Yuwang Biological Nutrition's adjusted net profit for the first half of 2025 is 35.4 million RMB, a decrease of 59.6% compared to the same period last year [5] Group 4 - Velantra has invested 19 million USD to acquire a 15% stake in Yuwang Biological Nutrition [7][11] - The board of directors includes Liu Rucui as the chairman and non-executive director, with Zhang Jianquan and Zang Xiurui as executive directors [7] - Prior to Velantra's investment, Yuwang Biological Nutrition was primarily a family-owned business [13]

安踏体育(02020)发布公告，于2025年8月27日，本公司的间接全资附属公司安卡控股与锐源及赏泰各自 订立股份认购协议，锐源及赏泰有条件同意认购而安卡控股有条件同意按相关对价配发及发行合共2500 股认购股份。 待认购事项完成后，由于安卡控股的已发行股份总额为发行认购股份所扩大，本公司透过安卡体育于安 卡控股持有的间接实益权益将会由100%摊薄至80%。因此，认购事项构成视作出售本公司所持有安卡 控股的20%股权。 安卡控股是为了持有"Jack Wolfskin"业务而设立的特殊目的公司。 继本集团于今年较早时间成功完成收购"Jack Wolfskin"业务后，本公司正规划下一阶段发展。董事认为 认购事项将扩大安卡控股的资本基础，符合并有利于"Jack Wolfskin"业务的增长策略。 此外，向赏泰(待于交割前完成架构重组后其将由主要为本集团高级管理层及僱员的利益而设的信托所 持有)发行相关认购股份，可激励本集团高级管理层及雇员并将彼等的财务利益与本集团保持一致，及 推动彼等继续为"Jack Wolfskin"业务的长远成长及发展作出贡献。 ...

Core Viewpoint - Goldman Sachs is facilitating a capital raise for Millennium Management, aiming to sell 10% to 15% of the company at a valuation of approximately $14 billion, with a fundraising target of up to $2 billion [1] Group 1: Fundraising Details - Millennium Management, led by Izzy Englander, is seeking to sell equity with a minimum subscription threshold of $1 million and a maximum of $20 million [1] - The total fundraising could reach $2 billion, with about half of the funds coming from Goldman Sachs' Petershill division and the remainder from existing large institutional clients such as sovereign wealth funds [1] Group 2: Investor Outreach - Goldman Sachs has begun extensive outreach to potential investors, including high-net-worth individuals and employees from Millennium Management's main competitors [1] - The collaboration with Petershill indicates Millennium Management's strategy to broaden its potential buyer base from institutions to wealthy individuals [1]